Salon Today

MARCH 9, 2025

In our 9th day of the 2025 SALON TODAY 200, we meet the salons and spas who master a number of best practices to fuel their growth, including Heather Spencer and Adreanne Gellise-Budzinski, owners of A Spencer Gellise Salon in Bay City, Michigan.

Salon 105

Salon 105

The Dermatology Digest

MARCH 9, 2025

Leo Pharma’s delgocitinib cream produces a deep, consistent, and/or maintained response in a subgroup of super-responders with moderate-to-severe Chronic Hand Eczema (CHE), according to a late-breaker presented at the American Academy of Dermatology’s 2025 Annual Meeting in Orlando, FL. The subgroup analysis was based on the treatment response in patients with moderate-to-severe CHE treated with delgocitinib cream 20 mg/g for 16 weeks compared to patients treated with the cream vehic

Eczema 36

Eczema Dermatology Treatments Marketing 36

Dermatology Times

MARCH 9, 2025

Expect exciting news in the treatment of port-wine birthmarks, Kristen Marie Kelly, MD, told AAD Annual Meeting attendees.

Treatments 70

Treatments Therapy 70

Skin Inc

MARCH 9, 2025

So, how do you make your brand stand out? The answer lies in the art of using relevant, engaging content to draw in new customersbecause lets be honest, great skin care deserves great storytelling.

Branding 56

Branding Marketing 56

Dermatology Times

MARCH 9, 2025

Gold emphasized the necessity of recognizing and managing complications in aesthetic dermatology to ensure patient safety and optimal outcomes.

Dermatology 67

Dermatology Safety Management 67

The Dermatology Digest

MARCH 9, 2025

Dupilumab (Dupixent, Sanofi & Regeneron) hit all the key primary and secondary endpoints in a study of adults with Bullous Pemphigoid (BP). Results from the pivotal ADEPT Phase 2/3 trial were shared in a late-breaking oral presentation at the 2025American Academy of Dermatology(AAD) Annual Meeting in Orlando, FL. In February 2025, theU.S. Food and Drug Administration(FDA)acceptedfor Priority Review the supplemental Biologics License Application for dupilumab to treat BP.

Sustainability 36

Sustainability Hospital Clinic Dermatology 36

Dermatology Times

MARCH 9, 2025

Adamson dives deep into artificial intelligence, molecular testing, and melanoma overdiagnosis.

Dermatology 45

Dermatology 45

Dermatology Times

MARCH 9, 2025

Anabela Cardoso, MD, provides data on the phase 3 BRAVE-AA-PEDS trial, the largest JAK inhibitor study dedicated to adolescents with severe alopecia areata, at AAD.

45

45

Dermatology Times

MARCH 9, 2025

At the AAD Annual Meeting, Roy G. Geronemus, MD, emphasized the importance of early interventions for port wine stains.

41

41

Dermatology Times

MARCH 9, 2025

JiaDe Yu, MD, discussed important clinical issues in allergic contact dermatitis at the AAD Annual Meeting.

Dermatitis 41

Dermatitis Treatments Clinic 41

Dermatology Times

MARCH 9, 2025

At AAD 2025, Raj Chovatiya, MD, PhD, MSCI, explored the role of social determinants in AD, HS, and PsO, emphasizing the need for improved clinical recognition and inclusive research.

Clinic 41

Clinic 41

Dermatology Times

MARCH 9, 2025

AbbVies phase 2 study demonstrates how upadacitinib reduces type 1 inflammation and boosts melanocyte biomarkers to drive vitiligo response.

41

41

Dermatology Times

MARCH 9, 2025

Findings suggest that most patients on risankizumab met or exceeded the National Psoriasis Foundations treatment goals.

Treatments 36

Treatments 36